Skandinaviska Enskilda Banken AB publ Sells 15,527 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Skandinaviska Enskilda Banken AB publ trimmed its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 32.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 32,100 shares of the biopharmaceutical company’s stock after selling 15,527 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Halozyme Therapeutics were worth $1,541,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of the stock. GSA Capital Partners LLP bought a new position in Halozyme Therapeutics in the third quarter worth approximately $217,000. CIBC Asset Management Inc purchased a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth $211,000. Natixis Advisors LLC grew its position in shares of Halozyme Therapeutics by 86.7% during the 3rd quarter. Natixis Advisors LLC now owns 121,560 shares of the biopharmaceutical company’s stock worth $6,958,000 after buying an additional 56,461 shares in the last quarter. TrinityPoint Wealth LLC purchased a new position in shares of Halozyme Therapeutics during the third quarter valued at $214,000. Finally, Quest Partners LLC raised its holdings in shares of Halozyme Therapeutics by 1,386.0% in the third quarter. Quest Partners LLC now owns 9,793 shares of the biopharmaceutical company’s stock valued at $561,000 after acquiring an additional 9,134 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Price Performance

NASDAQ HALO opened at $62.95 on Tuesday. The firm’s fifty day simple moving average is $57.05 and its two-hundred day simple moving average is $54.63. The firm has a market capitalization of $7.75 billion, a P/E ratio of 18.35, a P/E/G ratio of 0.42 and a beta of 1.32. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a 12-month low of $37.73 and a 12-month high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Benchmark reiterated a “buy” rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Piper Sandler boosted their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Finally, Wells Fargo & Company dropped their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.78.

Insider Activity

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the sale, the senior vice president now owns 185,453 shares of the company’s stock, valued at approximately $10,765,546.65. The trade was a 5.12 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jeffrey William Henderson sold 5,000 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total transaction of $293,450.00. Following the completion of the transaction, the director now directly owns 33,611 shares of the company’s stock, valued at approximately $1,972,629.59. This represents a 12.95 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 31,697 shares of company stock worth $1,754,451 over the last 90 days. 2.40% of the stock is currently owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.